NCT04445701View on ClinicalTrials.gov

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

August 5, 2022

Study Completion Date

November 14, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

AO-176

Humanized monoclonal antibody (mAb) targeting CD47

DRUG

AO-176 + Dex

Humanized mAb targeting CD47 plus dexamethasone

DRUG

AO-176 + Dex + Bort

Humanized mAb targeting CD47 plus dexamethasone plus bortezomib

Trial Locations (6)

30322

Emory University, Atlanta

32224

Mayo Clinic, Jacksonville

53226

Medical College of Wisconsin and Froedtert Hospital, Milwaukee

55905

Mayo Clinic, Rochester

85054

Mayo Clinic, Phoenix

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Arch Oncology
All Listed Sponsors
lead

Arch Oncology

INDUSTRY

NCT04445701 - Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter